为您找到相关结果约500个

你是不是要搜索 期刊Safety,+pharmacokinetic,+pharmacodynamic,+and+efficacy+data+for+the+oral+MEK+inhibitor+trametinib:+a+phase+1+dose-escalation+trial. 点击跳转

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348)in a phase 1 dose-escalation trial

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinicaltrial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novelangiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalationtrial

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3Kand mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral METinhibitor tepotinib to determine the recommended phase II dose

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With AcuteMyeloid Leukemia With RAS Mutations: A Phase II Study

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor

Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versusstandard dose in East Asians: a systematic review

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration A Phase 1 Dose-Escalation

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopaniband MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast

为您找到相关结果约500个

共500条页码: 1/34页15条/页